AstraZeneca has announced the extended TGA approval of TAGRISSO (osimertinib) to include its use as adjuvant therapy after tumour resection in patients with NSCLC whose tumours have activating EGFR mutations. …
Latest Video
New Stories
-
GSK to buy Nuvalent in a major move to acquire rights to late stage lung cancer candidates
June 10, 2026 - - Latest News -
Australian company secures US fast track for CAR-T in blood cancers
June 10, 2026 - - Latest News -
Industry campaign highlights MFN risk to US jobs and the broader economy
June 10, 2026 - - Latest News -
R&D tax shake up risks sending Australia’s biotech talent and jobs overseas
June 9, 2026 - - Latest News -
It was an unintentionally revealing discussion about the history and reality of agreements
June 9, 2026 - - Latest News -
New report highlights the potential health-system benefits of pharmacist prescribing
June 9, 2026 - - Latest News -
Rare Cancers Australia co-founder Kate Vines recognised in King's Birthday Honours
June 8, 2026 - - Latest News